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Introduction
Rheumatoid arthritis (RA) is a systemic in-
flammatory disease characterized by joint 
pain, swelling, stiffness, and progressive 
destruction of the small joints. Patients 
with RA should be treated appropriately 
in order to improve symptoms and inhibit 
structural joint damage. Treatment of RA 
has improved over the past decade. Of the 
treatment options available, Non-steroidal 
anti-inflammatory drugs (NSAID) are the 
most widely used agents for symptomatic 
treatment. However, these drugs have sever-
al adverse effects (1). More options are low-
dose glucocorticoids which have a modify-
ing effect on structural damage in early RA 
(2) and disease-modifying antirheumatic 
drugs (DMARDs) such as hydroxychloro-
quine, methotrexate (MTX), leflunomide, 
cyclosporine, sulfasalazine, azathioprine, 
cyclophosphamide and biologics (3, 4). To 
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Objective. to evaluate changes in the expression of tumor necrosis 
factor-α in patients with rheumatoid arthritis submitted to photother-
apy. Materials and methods. This was an open label study, enrolling 
ten patients. The phototherapy scheme within a range of 425 to 650 
nm, 11.33 Joules/cm2, 30 cm above the chest was as follows: a) 45-min 
daily sessions from Monday to Friday for 2 to 3 months; b) three, 45-
min weekly sessions for 1 to 2 months; c) twice weekly 45-min ses-
sions for 1 to 2 months, and d) one weekly session for 1 to 2 months 
until completion. Erythrocyte sedimentation rate, C-reactive protein 
and rheumatoid factor were measured in peripheral blood and tumor 
necrosis factor-α, interleukin-1β, and interleukin-10 in leukocytes by 
quantitative real-time Reverse transcriptase-Polymerase chain reac-
tion. In all the patients the next indexes: Karnofsky scale, Rheumatoid 
Arthritis-specific quality of life instrument, Steinbrocker Functional 
Capacity Rating and the Visual Analog Scale were evaluated. Results. 
Erythrocyte sedimentation rate, C-reactive protein, and rheumatoid 
factor declined notoriously after the indicated sessions. In gene ex-
pression, there was a tendency in tumor necrosis factor-α to decrease 
after 1 month, from 24.5±11.4 to 18±9.2 relative units, without reach-
ing a significant statistical difference. The four tested indexes showed 
improvement. Conclusion. Phototherapy appears to be a plausible 
complementary option to reduce the inflammatory component in 
rheumatoid arthritis.
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date, anti-Tumor necrosis factor-α (TNF-α) 
agents represent a milestone in RA treat-
ment (5-7).
Although new therapies are increasingly 
available (8), a significant unmet medical 
need continues for patients with RA who 
have had inadequate response to prior treat-
ments and require safe and effective therapy 
using a different mechanism of action. Al-
ternative and complementary treatments for 
RA have been explored in many countries. 
One of these alternatives is phototherapy 
with diverse light spectra including Ultra-
violet (UV), laser Photodynamic therapy 
(PDT), Light emitting diodes (LED) etc. (9, 
10). 
Our main objective was to evaluate the 
changes in the expression of TNF-α, Inter-
leukin (IL)-1β and IL-10 in patients with RA 
while they are being submitted to a comple-
mentary treatment with phototherapy.
Methods
Study population
This was an open label study to evalu-
ate the effect of phototherapy in patients 
with RA who met the criteria established 
by the American College of Rheumatology 
(ACR) (11). We included consecutive pa-
tients attending the Research Department, 
of the Maternal-Perinatal Hospital “Mónica 
Pretelini Sáenz” (HMPMPS), Health Insti-
tute of the State of Mexico (ISEM), Toluca, 
Mexico, in the period 2010-2012. Those with 
fewer than four criteria of the ACR, previous 
fractures, chronic diseases that limit func-
tional capacity, other arthropathies, overlap 
syndromes, and no agreement of the patient 
to participate in the study were excluded. 
Patients who failed to comply with the pho-
totherapy treatment program or severe dis-
ease progression were discarded. There was 
no any kind of restriction to the prescribed 
pharmacotherapy.
Phototherapy
With the patient in supine position, after 
registering vital signs (blood pressure, heart 
rate, respiratory rate, and temperature), 
weight, height, and capillary glucose deter-
mination, we proceeded to place the pho-
totherapy lamp (Federal Ministry of Health 
registration number: 1694E95) within a 
range between 425 and 650 nm, 11.33 Joules/
cm2, 30 cm above the chest. The decision of 
placing the lamp above the chest was based 
on the location of the great vessels and the 
thymus as the aim of the treatment was to 
get a systemic effect rather than a local one.
The phototherapy scheme was the fol-
lowing: a) 45-min daily sessions from Mon-
day to Friday for 2 to 3 months; b) three 
45-min sessions per week for 1 to 2 months; 
c) twice weekly 45-min sessions for 1 to 2 
months, and d) one weekly session for 1 to 2 
months until completion. Weekly frequency 
and progressive reduction of phototherapy 
sessions were determined according to the 
patients’ own improvement. 
Clinical follow-up
The patients’ data was obtained from their 
medical history. Clinical evaluation was per-
formed by the Research Team Leader once 
weekly, including the next indexes: Kar-
nofsky scale, Rheumatoid Arthritis-specific 
quality of life (RAQoL) instrument, Stein-
brocker Functional Capacity Rating and the 
Visual Analog Scale (VAS). An essential as-
pect of the study was absolute respect for the 
management, evaluation, and subsequent 
appointments instituted by the treating 
Rheumatologist. Phototherapy alone was 
considered for naïve patients with contrain-
dications for the antirheumatic drugs.
Biochemical assessment
Laboratory tests were done in the first clini-
cal visit and 4 weeks after the initiation of 
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treatment. Fasting blood samples (10 ml) 
were taken at the HMPMPS Laboratory at 
an early-morning after an overnight fast. 
Serum samples were analyzed for globulin 
(Dimension Rx L Max, Dade Behring, USA), 
hemogram (Advia 120, Bayer Health, USA), 
Erythrocyte sedimentation rate (ESR), C-
reactive protein (CRP), and Rheumatoid 
factor (RF). All these tests were measured 
according to standardized procedures rec-
ommended by the International Federation 
of Clinical Chemistry and Laboratory Medi-
cine (IFCC).
Leukocyte collection and storage
Blood samples were taken by venipuncture 
in tubes (Vacutainer) containing Ethylene-
diaminetetraacetic acid (EDTA) as anticoag-
ulant for subsequent centrifugation at 2,500 
rpm for 10 min. Using a 1-ml micropipette, 
leukocytes were separated and deposited in 
sterile Eppendorf® 1.5-ml tubes. Once sepa-
rated, the leukocytes were purified in 1 ml 
Red blood cell (RBC) ACK Lysing buffer 
(ACK), stirring by gentle inversion and al-
lowing these to sit for 1 min at 30°C. Follow-
ing this, they were centrifuged at 2,000 rpm 
for 5 min, the supernatant was discarded, 
and 1 ml of ACK was again added, repeating 
the process until visualizing a pellet with-
out RBC. The final step was the addition of 
100 µl of phosphate buffer and resuspension 
for further storage at -80°C (Forma -86ºC 
ULT Freezer, Thermo Electron Corpora-
tion, USA) until analysis, which was carried 
out in the Laboratory of Molecular Biology, 
Medical Sciences Research Center (CIC-
MED), Autonomous University of the State 
of Mexico (UAEMex).
Gene expression
Messenger RNA (mRNA) was isolated using 
the Magna Pure LC RNA Isolation Kit III 
and retrotranscribed with the Transcriptor 
High Fidelity cDNA Synthesis Kit (Roche) 
to obtain complementary DNA (cDNA). 
Samples were then quantified using a nano-
photometer set (Nano Photometer, Implen) 
at two wavelengths (260 nm and 280 nm), 
with an acceptable degree of purity between 
1.8 and 2. 
Quantitative real-time Reverse Tran-
scriptase-Polymerase Chain Reaction (qRT-
PCR) was performed in a 7500 Fast Real 
Time PCR System (Applied Biosystems, Ap-
plera UK, Cheshire, UK), using the TaqMan® 
Gene Expression Assays (Life Technologies, 
USA) for TNF-α (Catalog #4331182), IL-
1β (Catalog #4331182), and IL-10 (Catalog 
#4331182), following the manufacturer’s in-
structions. The relative expression of these 
genes was calculated through the 2−ΔΔCT 
method against 18S (NCBI: NC_000012.11) 
as follows: fw: 5’-ctttggtatcgtggaaggactc-3’, 
and rv: 5’-gtagaggcagggatgatgttct-3’ (Cata-
log #Hs99999901-s1; Life Technologies).
Ethics statement
The protocol was approved by the Research 
Committee of the HMPMPS (November 
2010) and followed the Declaration of Hel-
sinki indications. All patients were asked to 
sign written informed consent. 
Statistical analysis
Descriptive analysis, Wilcoxon test to com-
pare whether the group presented differ-
ences through time and Spearman correla-
tion were performed with the SPSSP v. 17 
program. A difference was considered sig-
nificant at p≤0.05. Results are expressed as 
absolute numbers, means ± standard devia-
tion (SD) for all variables except TNF-α, IL-
1β and IL-10 that are expressed as absolute 
numbers, means ± standard error (SE).
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Results
Anthropometric data
A total of 10 women, mean age of 41.2±8.8 
years, with RA were enrolled for this study. 
Mean time within the protocol was 140±7.7 
days. The average number of antirheumatic 
drugs that patients were taking at the time 
of the initiation of the protocol was of 3.7 
(Table 1). 
Clinical evolution
Table 2 shows the results of the evaluated 
scales. While the Karnofsky increased 1.3 
times, the RaQol questionnaire was reduced 
by almost half. Additionally, the Steinbrock-
er Functional Capacity Rating improved 
from Class III to Class II. Finally, the VAS 
showed a reduction in pain from “dreadful” 
to “annoying”.
Laboratory analysis
There were no differences in the hemato-
logical evaluation. The acute inflammation 
variables declined notoriously after the indi-
cated sessions. In gene expression, there was 
a tendency in TNF-α to be decreased after 
1 month, from 24.5±11.4 to 18±9.2 relative 
units without reaching significant statistical 
difference. Neither IL-1β nor IL-10 showed 
significant statistical differences (Table 2).
IL-1 and IL-10 showed a significant 
negative correlation in their trends (-0.829, 
p=0.042). On the contrary, there was a posi-
tive correlation in the reduction values of 
TNF and the VAS (0.894, p=0.041). 
The Karnofsky scale showed a negative 
correlation with the RaQol (-0.851, p=0.002) 
and VAS (-0.757, p=0.011) scales. The last 
scale showed a positive correlation with 
RaQol (0.665, p=0.036), Steinbrocker Func-
tional Capacity Rating (0.774, p=0.009) and 
with the TNF-α reduction (0.894, p=0.041).
Table 1 General characteristics of the population
Case Age* Disease duration† Concomitant treatment
1 41 4 Metamizol 500 mg/day PO‡; Paracetamol 650 mg/day PO; Ketorolac 30 mg/day IM‡ 
2 47 60
Methotrexate 10 mg/week PO; Hydroxychloroquine 200 mg/day PO; Acemetacin 60 
mg/12 h PO; Methylprednisolone 40 mg bimonthly IM; Diclofenac 75-150 mg/day 
PO
3 32 58 Methotrexate 15 mg/week PO; Sulfasalazine 500 mg/12 h PO; Diclofenac 100 mg/12 h PO
4 41 9 Prednisone 10 mg/day PO; Diclofenac 100 mg/12 h PO;Paracetamol 500 mg/12 h PO; Meloxicam 15 mg IM only 2 doses
5 44 59 Methotrexate 5 mg/week PO; Deflazacort 2 mg/day PO;Diclofenac 100 mg/12 h PO
6 44 45 Methotrexate 15 mg/week PO; Sulfasalazine 500 mg/8 h PO; Prednisone 20 mg/day, 10 days/month PO; Acemetacin 60 mg/12 h PO; Fluoxetine 20 mg/day PO
7 48 34 Leflunomide 20 mg/day PO; Sulfasalazine 500 mg/12 h PO; Diclofenac 100 mg/12 h PO
8 42 2 Leflunomide 20 mg/day PO; Hydroxychloroquine 200 mg/day PO; Deflazacort 3 mg/day PO; Naproxen 275 mg/12 h PO; Paracetamol 300 mg/12 h PO
9 21 17 Prednisone 75 mg/day P.O. 
§Dexamethasone 8 mg IM only 4 doses; §Ibuprofen 400 
mg/12 h PO
10 52 120 Chloroquine 150 mg/12 h PO; Sulfasalazine 2.5 g/day PO; Diclofenac 100 mg/day PO
*Years; †Months; PO=oral administration; IM=intramuscular; ‡Self-medication, §This treatment was suspended 7 months previous to the study 
due to pregnancy.
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Discussion
DMARDs, TNF inhibitor treatments, or 
their combination are considered first-line 
treatment (12) in RA, but collateral effects 
such as hepatotoxicity and nephrotoxicity 
are commonly associated with the former 
option. In addition, immunosuppression 
predisposes to increased risk of infection, 
the potential for development of certain 
types of malignancy, as well as the signifi-
cant increased cost of therapy. 
It has been demonstrated that UV radia-
tion poses an immunosuppression effect due 
in part to changes in the expression of IL-
10, transformation of urocanic acid from its 
trans to cis isomer, and induction of CD4+ 
CD25+ T regulatory cells (9). Evidence indi-
cates that phototherapy exerts a significant 
impact on neutrophils, the effect of which 
varies according to the specific type of pho-
totherapy (13). 
A previous study by Goats et al. tested 
the therapeutic effects of combined low-in-
tensity laser and phototherapy upon the ar-
ticular, systemic, and functional sequelae of 
RA affecting weight-bearing joints without 
finding significant differences between the 
active or placebo cohorts (14). To date, the 
majority of trials have unsuccessfully tested 
laser therapy with a wide range of parame-
ters in Joules and wavelength (15). Contrari-
wise, the present study noted a tendency of 
TNF decrement.
In mice models, LED irradiation has 
been effective for inhibition of the inflam-
matory reactions caused by RA within a 
period of four weeks (16); but to the best 
of our knowledge, the present study is the 
first specifically designed to investigate the 
short-term effect of visible light and changes 
in peripheral TNF-α, IL-1β, and IL-10 ex-
pression. Despite the lack of significant dif-
ferences after the month of follow up, we 
Table 2 Clinical and laboratorial characteristics
Characteristics
Values of laboratory tests
p value
Basal After‡
Hb (g/dl)*  12.4±1.6 12.7±1.6 0.134
Ht (volume %)* 38.6±4 39.35±4.9 0.386
Leukocytes (cells/mm3)* 6390±1757 6060±1509 0.327
Granulocytes (cells/mm3)* 4554±1561 4302±1414 0.285
Lymphocytes (cells/mm3)* 1360±536 1270±309 0.386
Monocytes (cells/mm3)* 284±80 296±88 0.203
CRP (titers)* 1:204 ±169 1:122 (±186) 0.008
ESR (mm/h)* 45±14 38.6±13 0.017
Rheumatoid factor (titers)* 1:808 ±1554 1:178 (±387) 0.026
IL-1β (RU)† 0.23±0.18 0.66±0.32 0.917
IL-10 (RU)† 1.6±1.2 0.58±0.32 0.374
TNF-α (RU)† 24.5±27.9 18±22.6 0.249
Karnofsky scale (points)* 46±17.1 64±12.6 0.005
RAQoL (points)* 25.7±8.5 13.9±6.1 0.001
VAS (points)* 6.9±2.4 3.2±2.2 0.001
*Mean±SD; †Mean±SE; ‡One month of phototherapy; CRP=C reactive protein; ESR=Erythrocyte sedimentation rate; Hb=Haemoglobin; 
Ht=Haematocrit; IL=Interleukin; RAQoL=Rheumatoid Arthritis-specific Quality of Life; RU=Relative units; TNF-α=Tumor necrosis factor-α; 
VAS=Visual Analogue Scale.
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did find significant correlation between the 
clinical improvement and the reduction in 
TNF-α.
The primary cellular effects of photo-
therapy are related with the interaction of 
photons and the intracellular molecules that 
absorb them, i.e., the cytochromes. Visible 
light is absorbed by cytochromes, many of 
which are located in the mitochondria. It 
has also been postulated that light can act 
as a catalyst, influencing molecules, organ-
elles, and cells without being absorbed (17). 
Whether or not the primary effects of light 
induce the changes in inflammatory vari-
ables is a matter that has yet to be discerned. 
In an initial attempt, this study shows a pos-
sible reduction in TNF-α secondary to the 
phototherapy sessions, but more studies are 
needed to clarify this issue.
A limitation of this study is the low num-
ber of participants. Notwithstanding, the 
quantification of gene expression of inflam-
matory markers along with the clinical scale 
evaluation, gives a good support for a possi-
ble recommendation of phototherapy in RA. 
Another limitation of this study in terms of 
the interest for the clinician is that we didn’t 
collect any activity index of the disease such 
as DAS28 or SDAI which are the topic of a 
new project.
Conclusion
Phototherapy could be useful to treat pa-
tients with RA, which is clearly evident with 
the reduction in the following inflammatory 
markers: ESR, CRP, and RF. Due to scarce 
knowledge on the mechanism of action of 
phototherapy, the results should be treated 
with caution. 
What is already known on this subject 
Rheumatoid arthritis (RA) is a chronic and painful inflamma-
tory disease. To date, anti-Tumor necrosis factor-α agents rep-
resent a milestone of RA treatment in addition to non-steroidal 
anti-inflammatory drugs (NSAID), low-dose glucocorticoids, 
and Methotrexate. Despite the development of new pharma-
cological therapies, alternative and complementary treatments 
for RA have been explored extensively.
What this study adds
As a complementary option, phototherapy with diverse light 
spectrums has shown potential clinical utility in treating RA. 
In this line, we evaluated the effect on inflammatory markers 
in RA after 1 month of phototherapy within a range of 425 to 
650 nm, 11.33 Joules/cm2, yielding a reduction in the levels of 
Erythrocyte sedimentation rate, C-reactive protein, and rheu-
matoid factor.
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